A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor
Clinical trial NCT02640833 · WITHDRAWN
Trial details
- NCT number
- NCT02640833
- Sponsor
- AbbVie
- Status
- WITHDRAWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-07-01
- Primary completion
- 2020-01-01
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.